CA2859934A1 - Comete de hayley ii - Google Patents
Comete de hayley ii Download PDFInfo
- Publication number
- CA2859934A1 CA2859934A1 CA2859934A CA2859934A CA2859934A1 CA 2859934 A1 CA2859934 A1 CA 2859934A1 CA 2859934 A CA2859934 A CA 2859934A CA 2859934 A CA2859934 A CA 2859934A CA 2859934 A1 CA2859934 A1 CA 2859934A1
- Authority
- CA
- Canada
- Prior art keywords
- cultivar
- cannabidiolic acid
- cannabis
- cannabinoid
- profile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims abstract description 14
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 claims abstract description 13
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 13
- 239000003557 cannabinoid Substances 0.000 claims abstract description 13
- 241000218236 Cannabis Species 0.000 claims abstract description 10
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims abstract description 6
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 6
- 229960004242 dronabinol Drugs 0.000 claims abstract description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 6
- 208000002193 Pain Diseases 0.000 claims abstract description 3
- 206010015037 epilepsy Diseases 0.000 claims abstract description 3
- 230000002068 genetic effect Effects 0.000 claims abstract description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract description 6
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract description 6
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract description 5
- 229950011318 cannabidiol Drugs 0.000 abstract description 5
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 229940065144 cannabinoids Drugs 0.000 abstract description 3
- 238000001502 gel electrophoresis Methods 0.000 abstract description 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 229960003453 cannabinol Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 238000010367 cloning Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- ZLHQMHUXJUPEHK-UHFFFAOYSA-N Cannabivarin Natural products CCCc1cc(O)c2c(OC(C)(C)c3ccccc23)c1 ZLHQMHUXJUPEHK-UHFFFAOYSA-N 0.000 description 1
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/04—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859934A CA2859934A1 (fr) | 2014-09-22 | 2014-09-22 | Comete de hayley ii |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859934A CA2859934A1 (fr) | 2014-09-22 | 2014-09-22 | Comete de hayley ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2859934A1 true CA2859934A1 (fr) | 2016-03-22 |
Family
ID=55539873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2859934A Abandoned CA2859934A1 (fr) | 2014-09-22 | 2014-09-22 | Comete de hayley ii |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2859934A1 (fr) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| CN108743571A (zh) * | 2018-08-07 | 2018-11-06 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
| CN110632224A (zh) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | 一种麻类植物指纹图谱的建立方法 |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| US12121499B2 (en) | 2011-09-29 | 2024-10-22 | Gw Pharma Ltd. | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
-
2014
- 2014-09-22 CA CA2859934A patent/CA2859934A1/fr not_active Abandoned
Cited By (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US12121499B2 (en) | 2011-09-29 | 2024-10-22 | Gw Pharma Ltd. | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11311498B2 (en) | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11963937B2 (en) | 2014-06-17 | 2024-04-23 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10849860B2 (en) | 2014-10-14 | 2020-12-01 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10137095B2 (en) | 2014-10-14 | 2018-11-27 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10111840B2 (en) | 2014-10-14 | 2018-10-30 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US12064399B2 (en) | 2015-06-17 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| EP3769755A1 (fr) | 2015-08-10 | 2021-01-27 | GW Research Limited | Utilisation de l acide cannabidiolique dans le traitement de l'épilepsie |
| US11684598B2 (en) | 2015-08-10 | 2023-06-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US12064398B2 (en) | 2016-07-01 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Parenteral formulations |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| CN108743571B (zh) * | 2018-08-07 | 2020-10-02 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
| CN108743571A (zh) * | 2018-08-07 | 2018-11-06 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
| CN110632224B (zh) * | 2019-09-16 | 2022-02-15 | 福建省中科生物股份有限公司 | 一种麻类植物指纹图谱的建立方法 |
| CN110632224A (zh) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | 一种麻类植物指纹图谱的建立方法 |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US12102619B2 (en) | 2020-02-27 | 2024-10-01 | Jazz Pharmaceuticals Research Uk Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2859934A1 (fr) | Comete de hayley ii | |
| CA2737447A1 (fr) | "hayley's comet" | |
| Mikulic-Petkovsek et al. | Investigation of anthocyanin profile of four elderberry species and interspecific hybrids | |
| Ahn et al. | Dimethyl sulfoxide inhibits NLRP3 inflammasome activation | |
| Kipper et al. | Meta-analysis of the effects of endoparasites on pig performance | |
| Priyadarshini et al. | Astaxanthin inhibits cytokines production and inflammatory gene expression by suppressing IκB kinase-dependent nuclear factor κB activation in pre and postpartum Murrah buffaloes during different seasons | |
| NZ715957A (en) | Compartmentalized method of nucleic acid delivery and compositions and uses thereof | |
| Yang et al. | Resveratrol sustains intestinal barrier integrity, improves antioxidant capacity, and alleviates inflammation in the jejunum of ducks exposed to acute heat stress | |
| Gao et al. | Supplementation of xanthophylls decreased proinflammatory and increased anti-inflammatory cytokines in hens and chicks | |
| Liu et al. | Pod mildew on soybeans can mitigate the damage to the seed arising from field mold at harvest time | |
| CA2859927A1 (fr) | Empreinte genetique gcg et profil clhp | |
| Panjeshahin et al. | Genetic and morphological diversity of wild mint | |
| Dąbrowski et al. | Cannabinoids from Cannabis sp.: Mechanism of their activity and potential health benefits in human body | |
| RU2020119597A (ru) | Композиция для лечения пациента с респираторным заболеванием, обусловленным хроническим воспалением, способ получения и применение указанной композиции | |
| WO2021016676A1 (fr) | Procédés améliorés pour la production de plantes | |
| KR102545535B1 (ko) | 꾸지뽕 씨앗을 유효성분으로 함유하는 항균, 피부개선 또는 항알레르기용 조성물 | |
| BR112022011326A2 (pt) | Conjugado entre um biopolímero e um agente antimicrobiano fotoativável para combate de doenças fúngicas de interesse agrícola e métodos para produção dos ditos conjugados | |
| TWI702959B (zh) | 開發黃花蟛蜞菊的標準化與功效最佳化的草藥抽出物以及其用於治療疾病的用途 | |
| Mail et al. | Anti-hyphal properties of potential bioactive compounds for oral rinse in suppression of Candida growth | |
| US20240341254A1 (en) | Varin profiles | |
| US20230255159A1 (en) | Varin profiles | |
| CN109420173B (zh) | Gpr55及其调节剂在防治免疫系统疾病中的应用 | |
| Gocsik et al. | Impact of different production systems on health care costs in the Dutch broiler farms | |
| Yazdanpanah et al. | Determination of chemical composition and anti-fungal activities of aromatic water of Zataria multiflora Boiss. | |
| TW202330003A (zh) | 用於預防或治療癌症的組成物、其製法及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20170922 |
|
| FZDE | Discontinued |
Effective date: 20170922 |